autophagy related 7Genealiases: APG7-LIKE · APG7L · GSA7 · SCAR31
Q-omics provides the consensus-scored ATG7 profile across patient tissues and cancer cell-line models. ATG7 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, ATG7 is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, ATG7 protein abundance shows 21,146 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LIHC, and LSCC as cancer lineages where ATG7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ATG7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ATG7 survival associations across molecular data types. ATG7 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ATG7 RNA expression–survival associations across cancer types. High ATG7 expression shows unfavorable associations in LIHC and KICH, but favorable associations in DLBC, KIRC, UCEC and ESCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for ATG7 RNA expression.
This table summarizes ATG7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ATG7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ATG7 shows lower tumor expression in LUSC and higher tumor expression in LIHC, STAD, BLCA, COAD and KIRP. The LIHC box plot shows higher ATG7 RNA expression in tumor versus normal tissue (log2 FC = +0.967, t-test p < 0.001).
This table shows molecular features associated with ATG7 in patient tissues and cancer cell lines. In patient samples, ATG7 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ATG7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
